We are excited to share the completion of a stellar fundraising round fueled by industry leaders and driven by our unwavering commitment to revolutionizing healthcare. This investment round, spearheaded by Perlin Ventures and Enterprise Singapore, transcends borders and unites investors from across North America, Europe, and Asia. Their belief in our vision is a powerful vote of confidence that propels us towards ambitious global expansion.
Our sights are set on aggressive growth in key regional markets like Hong Kong, Malaysia, Thailand, India, and strategic pockets of Europe and North America. This expansion will be powered by three core pillars:
- R&D and Product Development: We will bolster our innovation engine to continuously refine our solutions and cater to diverse patient needs across the globe.
- Enhanced Manufacturing and Supply Chain: As we scale, we will build robust infrastructure to ensure efficient product delivery and inventory management, guaranteeing seamless care for every patient.
- Talent Acquisition and Local Teams: We will attract top-tier talent and establish local teams in strategic locations, fostering deeper customer engagement and cultural understanding.
But beyond capital, this round brings invaluable expertise. Our investors encompass orthopaedic surgeons, medical device experts, and AI specialists, providing a wealth of knowledge and guidance in commercial strategy, product development, and market entry. Their network opens doors to new customers, future investments, and revenue streams in untapped markets, accelerating our ascent.
The funds will directly power our growth through strategic investments in marketing and sales. We will strengthen existing sales forces in our established markets (North America, Europe, and Asia) and cultivate local teams in high-potential regions, maximizing market penetration and brand awareness.
Our fundraising target of five million US Dollars is the fuel that ignites this global expansion and empowers us to attract highly skilled talent. Local offices in Hong Kong, Europe, and the US will soon become our springboards, propelling us closer to patients worldwide.
We aim to close the first tranche of our Series A round within the first six months of 2024, paving the way for even greater achievements.
The future beckons with endless possibilities. We see tremendous potential in Southeast Asia (Hong Kong, Malaysia, India, and Thailand), Europe (Germany, Netherlands, Switzerland, and UK), and North America (US). These markets represent vast, untapped opportunities, and we are poised to capitalize on them.
At Kinexcs, we are driven by a relentless pursuit of innovation and a profound desire to improve lives. With the unwavering support of our investors, partners, and dedicated team, we are confident in achieving our ambitious goals and reshaping the medical technology landscape.
